Transcription-controlled gene therapy against tumor angiogenesis

Journal of Clinical Investigation

Volumn 113, Issue 7, 2004, Pages 1017-1024

  Greenberger, Shoshana ^a,b,c   Shaish, Aviv ^a,b,c   Varda Bloom, Nira ^a,b   Levanon, Keren ^a,b   Breitbart, Eyal ^c   Goldberg, Iris ^a,b   Barshack, Iris ^a,b   Hodish, Israel ^a,b   Yaacov, Niva ^c   Bangio, Livnat ^c   Goncharov, Tanya ^d   Wallach, David ^d   Harats, Dror ^a,b,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Vascular Biogenics Ltd   (Israel)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYTOKINE RECEPTOR; DEATH RECEPTOR; FAS ANTIGEN; PREPROENDOTHELIN 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CHIMERA; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; ENDOTHELIUM CELL; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IN VITRO STUDY; LEWIS CARCINOMA; MALE; MELANOMA B16; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SENSITIZATION; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD95; APOPTOSIS; CATTLE; ENDOTHELIAL CELLS; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 11144354459     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200420007     Document Type: Article

References (40)

1. Hanahan, D., and Folkman, J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.
2. Denekamp, J. 1993. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br. J. Radiol. 66:181-196.
3. Claesson-Welsh, L., et al. 1998. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc. Natl. Acad. U. S. A. 95:5579-5583.
4. Benjamin, L.E., and Keshet, E. 1997. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl. Acad. Sci. U. S. A. 94:8761-8766.
5. Jaggar, R.T., Chan, H.Y., Harris, A.L., and Bicknell, R. 1997. Endothelial cell-specific expression of tumor necrosis factor-alpha from the KDR or E-selectin promoters following retroviral delivery. Hum. Gene Ther. 8:2239-2247.
6. Ozaki, K., et al. 1996. Use of von Willebrand factor promoter to transduce suicidal gene to human endothelial cells, HUVEC. Hum. Gene Ther. 7:1483-1490.
7. Yanagisawa, M., Kurihara, H., Kimura, S., Goto, K., and Masaki, T. 1988. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J. Hypertens. Suppl. 6:S188-S191.
8. Hu, J., Discher, D.J., Bishopric, N.H., and Webster, K.A. 1998. Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1 binding site on the antisense strand. Biochem. Biophys. Res. Commun. 245:894-899.
9. Marsden, P.A., and Brenner, B.M. 1992. Transcriptional regulation of the endothelin-1 gene by TNF-alpha. Am. J. Physiol. 262:C854-C861.
10. Kurihara, H., et al. 1989. Transforming growth factor-beta stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem. Biophys. Res. Commun. 159:1435-1440.
11. Harats, D., et al. 1995. Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter. J. Clin. Invest. 95:1335-1344.
12. Varda-Bloom, N., et al. 2001. Tissue-specific gene therapy directed to tumor angiogenesis. Gene Ther. 8:819-827.
13. Bu, X., and Quertermous, T. 1997. Identification of an endothelial cell-specific regulatory region in the murine endothelin-1 gene. J. Biol. Chem. 272:32613-32622.
14. Armentano, D., et al. 1997. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J. Virol. 71:2408-2416.
15. Verma, I.M., and Somia, N. 1997. Gene therapy: promises, problems and prospects. Nature. 389:239-242.
16. Tripathy, S.K., Black, H.B., Goldwasser, E., and Leiden, J.M. 1996. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat. Med. 2:545-550.
17. Pastore, L., et al. 1999. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther. 10:1773-1781.
18. Dengler, T.J., and Pober, J.S. 2000. Human vascular endothelial cells stimulate memory but not naive CD8+ T cells to differentiate into CTL retaining an early activation phenotype. J. Immunol. 164:5146-5155.
19. Dengler, T.J., Johnson, D.R., and Pober, J.S. 2001. Human vascular endothelial cells stimulate a lower frequency of alloreactive CD8+ pre-CTL and induce less clonal expansion than matching B lymphoblastoid cells: development of a novel limiting dilution analysis method based on CFSE labeling of lymphocytes. J. Immunol. 166:3846-3854.
20. Ashkenazi, A., and Dixit, V.M. 1998. Death receptors: signaling and modulation. Science. 281:1305-1308.
21. Kaplan, H.J., Leibole, M.A., Tezel, T., and Ferguson, TA. 1999. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat. Med. 5:292-297.
22. Volpert, O.V., et al. 2002. Inducer-stimulated Fas targets activated endothelium for destruction by antiangiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat. Med. 8:349-357.
23. Arai, H., Gordon, D., Nabel, E.G., and Nabel, G.J. 1997. Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. U. S. A. 94:13862-13867.
24. Schneider, P., et al. 1998. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187:1205-1213.
25. Boldin, M.P., et al. 1995. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J. Biol. Chem. 270:7795-7798.
26. Khatib, A.M., et al. 1999. Rapid induction of cytokine and E-selectin expression in the liver in response to metastatic tumor cells. Cancer Res. 59:1356-1361.
27. Jaffe, E.A., Nachman, R.L., Becker, C.G., and Minick, C.R. 1973. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 52:2745-2756.
28. Lifshitz, S., et al. 1998. Extensive apoptotic death of rat colonic cells deprived of crypt habitat. J. Cell. Physiol. 177:377-386.
29. McGrory, W.J., Bautista, D.S., and Graham, F.L. 1988. A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5. Virology. 163:614-617.
30. Bu, X., and Quertermous, T. 1997. Identification of an endothelial cell-specific regulatory region in the murine endothelin-1 gene. J. Biol. Chem. 272:32613-32622.
31. Goltsev, Y.V., et al. 1997. CASH, a novel caspase homologue with death effector domains. J. Biol. Chem. 272:19641-19644.
32. Hsu, H., Huang, J., Shu, H.B., Baichwal, V., and Goeddel, D.V. 1996. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity. 4:387-396.
33. Tamm, I., et al. 1998. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58:5315-5320.
34. Rensing-Ehl, A., et al. 1995. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur. J. Immunol. 25:2253-2258.
35. Ogasawara, J., et al. 1993. Lethal effect of the anti-Fas antibody in mice. Nature. 364:806-809.
36. Jaggar, R.T., Chan, H.Y., Harris, A.L., and Bicknell, R. 1997. Endothelial cell-specific expression of tumor necrosis factor-alpha from the KDR or E-selectin promoters following retroviral delivery. Hum. Gene Ther. 8:2239-2247.
37. Hood, J.D., et al. 2002. Tumor regression by targeted gene delivery to the neovasculature. Science. 296:2404-2407.
38. Kuo, C.J., et al. 2001. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc. Natl. Acad. Sci. U. S. A. 98:4605-4610.
39. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M.S. 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:404-407.
40. O'Reilly, M.S., Holmgren, L., Chen, C., and Folkman, J. 1996. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2:689-692.